Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1476482 | 1.00 | HSD17B10 (0.39) | HSD17B10ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL725089 | 1.00 | HSD17B10 (0.39) | HSD17B10ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL8651797 | 1.00 | HSD17B10 (0.39) | HSD17B10ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL17914309 | 1.00 | HSD17B10 (0.39) | HSD17B10ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL17914307 | 1.00 | HSD17B10 (0.39) | HSD17B10ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL723497 | 0.96 | HSD17B10 (0.41) | HSD17B10ALDH1A1TDP1SPHK2SPHK1 | |
| SCHEMBL1072348 | 0.91 | HSD17B10 (0.35) | HSD17B10ALDH1A1 | |
| SCHEMBL405717 | 0.88 | HSD17B10 (0.56) | HSD17B10ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL7146848 | 0.88 | ALDH1A1 (0.39) | HSD17B10ALDH1A1TDP1 | |
| SCHEMBL405722 | 0.88 | HSD17B10 (0.56) | HSD17B10ALDH1A1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180208590-A1 | NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2018-07-26 | — | — | US | disclosed |
| US-9944632-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20180016269-A1 | NOVEL COMPOUNDS AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2018-01-18 | — | — | US | disclosed |
| US-20090035696-A1 | PHOTORESIST COMPOSITION | KYOWA HAKKO CHEMICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016269-A1 | NOVEL COMPOUNDS AND USES THEREOF | ESR2, ESRRB, ESRRA | HSD17B10 309/4885ALDH1A1 2070/4885MEN1 3216/4885 |
| US-20180208590-A1 | NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ESR2, ESRRG, ESR1 | HSD17B10 256/4885ALDH1A1 706/4885MEN1 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.